### AGENDA

*Mayflower Renaissance Hotel, 1127 Connecticut Avenue NW*

#### Wednesday, February 26th

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>4:00-8:00 pm</td>
<td>Registration open</td>
<td>Grand Ballroom Promenade</td>
</tr>
<tr>
<td>6:30-8:30 pm</td>
<td>Welcome Reception: “A Celebration of Progress for Patients”</td>
<td>State Room</td>
</tr>
</tbody>
</table>

#### Thursday, February 27th

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:00 am-5:00 pm</td>
<td>Registration open</td>
<td>Grand Ballroom Promenade</td>
</tr>
<tr>
<td>7:00-8:15 am</td>
<td>General Breakfast</td>
<td>State Room</td>
</tr>
<tr>
<td>7:00-8:15 am</td>
<td>Young Investigators Breakfast (by invitation only)</td>
<td>Senate Room</td>
</tr>
<tr>
<td>8:30-8:45 am</td>
<td>Opening Remarks</td>
<td>Grand Ballroom</td>
</tr>
<tr>
<td>8:45-10:05 am</td>
<td>Intersection of Immunotherapeutics and Kinase Inhibitors:</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Current Treatments and Emerging Paradigms</td>
<td></td>
</tr>
<tr>
<td>8:45-9:10 am</td>
<td>Jedd Wolchok, Memorial Sloan-Kettering Cancer Center: Checkpoint blockade combination therapy</td>
<td></td>
</tr>
<tr>
<td>9:10-9:30 am</td>
<td>Neal Rosen, Memorial Sloan-Kettering Cancer Center: Combinatorial approaches to treating mutant BRAF melanomas</td>
<td></td>
</tr>
<tr>
<td>9:30-9:50 am</td>
<td>Mary Jo Turk, Dartmouth College: BRAF-inhibition and tumor immune-suppression: lessons from a mouse model</td>
<td></td>
</tr>
<tr>
<td>9:50-10:05 am</td>
<td>Michael Atkins, Georgetown Lombardi Cancer Center: Kinetics and effects of BRAF inhibitors on intratumoral immunity</td>
<td></td>
</tr>
<tr>
<td>10:05-10:20 am</td>
<td>BREAK</td>
<td></td>
</tr>
<tr>
<td>10:20-11:45 am</td>
<td>Biomarkers: The Key to Melanoma Prognosis and Treatment Outcomes</td>
<td></td>
</tr>
<tr>
<td>10:20-10:45 am</td>
<td>Meenhard Herlyn, Wistar Institute: Drivers in melanoma development and progression</td>
<td></td>
</tr>
<tr>
<td>10:45-11:05 am</td>
<td>Graeme Walker, Queensland Institute for Medical Research: Discovery of genes for melanoma development using the Collaborative Cross approach</td>
<td></td>
</tr>
<tr>
<td>11:05-11:25 am</td>
<td>Jeffrey Trent, Translational Genomics Research Institute (TGen): Personalized medicine for BRAF wild type melanoma</td>
<td></td>
</tr>
<tr>
<td>11:25-11:45 am</td>
<td>Suzanne Topalian, Johns Hopkins University: PD-1 pathway blockade: markers of response and mechanisms of resistance</td>
<td></td>
</tr>
</tbody>
</table>
Thursday, February 27th (cont.)

**11:45-12:15**  
**Special Lecture:** Stephen Baylin, Johns Hopkins University  
**Can Epigenetic Therapy Sensitize to Checkpoint Immunotherapy?**

**12:30-1:45 pm**  
**Lunch and Discussion**
- Connie Mack, Senior Policy Advisor, Liberty Partners Group LLC; Former U.S. Senator; and MRA Board Member
- Michael Milken, Chairman, the Milken Institute and MRA Board Member
- Cokie Roberts, Political commentator, NPR and ABC

**2:00-3:20 pm**  
**Therapeutic Targeting of NRAS Mutant Melanoma**
Chair: Levi Garraway

- 2:00-2:20  
  Douglas Faller, Boston University: Targeting NRAS as a therapeutic approach for melanoma

- 2:20-2:40  
  Xu Wu, Massachusetts General Hospital: Targeting NRAS palmitoylation in melanoma

- 2:40-3:00  
  Susana Ortiz-Urda, University of California, San Francisco: Mechanisms of resistance for constitutively-activated NRAS melanoma

- 3:00-3:20  
  Levi Garraway, Dana-Farber Cancer Institute: The development of rational therapeutic regimens for NRAS-mutant melanoma

**3:20-3:35**  
**BREAK**

**3:35-4:55 pm**  
**Combination Therapies for Melanoma**
Chair: Charles Drake

- 3:35-3:55  
  Kai Wucherpfennig, Dana-Farber Cancer Institute: Synergistic targeting of inhibitory T cell pathways in melanoma

- 3:55-4:15  
  Ramesh Rengan, Fred Hutchinson Cancer Research Center: RADVAX: Stereotactic body radiation therapy with ipilimumab in melanoma

- 4:15-4:35  
  Fan Pan, Johns Hopkins University: Targeting HIF-1 inhibitors in combination with Treg depleting drugs (cyclophosphamide) and targeted anti-melanoma therapy

- 4:35-4:55  
  Charles Drake, Johns Hopkins University: Combination therapy to augment anti-PD-1 in melanoma

**4:55 pm**  
**Closing Remarks:** Laura Brockway-Lunardi, MRA Scientific Program Director

**6:30-10:00 pm**  
**Reception and Dinner**
Dress: Casual
410 7th Street NW, (202) 556-2050
6:15-7:15 pm, Transportation provided to restaurant, Pick up at Desales Street entrance of hotel
6:30-7:30 Reception; 7:30 Dinner; 8:30 Line Dancing

www.curemelanoma.org
Friday, February 28th

7:00-10:00 am  Registration open..........................................................................................Grand Ballroom Promenade

7:00-8:30 am  General Breakfast..............................................................................................State Room

7:00-8:30 am  Industry Roundtable Breakfast (by invitation only).................................Colonial Room

“Development of adjuvant and neo-adjuvant therapies for melanoma and other cancers”

8:40-8:45 am  Opening Remarks Day 2: Louise Perkins, MRA Chief Science Officer

8:45-11:10  New Strategies for Target Discovery and Credentialing...............................Grand Ballroom

Chair: Glenn Dranoff

8:45-9:05  Jonathan Cebon, Ludwig Institute for Cancer Research, Melbourne-Austin Branch: Targeting inducible invasive cells in melanoma

9:05-9:25  Barbara Bedogni, Case Western Reserve University: Targeting melanocyte precursor pathways for melanoma therapy

9:25-9:50  Christopher Vakoc, Cold Spring Harbor Laboratory: A functional approach to targeted melanoma therapy

9:50-10:10  Chris Sander, Memorial Sloan-Kettering Cancer Center: Network models of signaling pathways and combinatorial therapy in melanoma

10:10-10:25  BREAK

10:25-10:45  Jeffrey Ravetch, Rockefeller University: Enhancing immunotherapeutic activity of agonistic anti-CD-40 antibodies

10:45-11:10  Glenn Dranoff, Dana Farber Cancer Institute: Human anti-MICA monoclonal antibodies for melanoma immunotherapy

11:10-12:10  Selected Therapeutic Approaches: Unanswered Questions, Future Roles

Chair: Paul Chapman, Memorial Sloan-Kettering Cancer Center

11:10-11:30  Surgery: Daniel Coit, Memorial Sloan-Kettering Cancer Center

11:30-11:50  Vaccines: Nina Bhardwaj, Icahn School of Medicine at Mount Sinai

11:50-12:10  Adoptive cell therapy: Steven Rosenberg, U.S. National Cancer Institute

12:10 pm  Closing Remarks: Louise Perkins

12:15-1:30 pm  General Lunch..................................................................................................State Room